Humana Inc. (NYSE:HUM) had its target price increased by equities researchers at BMO Capital Markets from $290.00 to $300.00 in a report released on Friday. The firm currently has an “outperform” rating on the insurance provider’s stock. BMO Capital Markets’ price objective would suggest a potential upside of 22.75% from the company’s previous close.
A number of other analysts have also recently commented on the company. Morgan Stanley reduced their price objective on Humana from $276.00 to $270.00 and set an “overweight” rating for the company in a research report on Thursday. Royal Bank Of Canada reiterated a “sector perform” rating and set a $242.00 price objective (down previously from $245.00) on shares of Humana in a research report on Thursday. Credit Suisse Group assumed coverage on Humana in a research report on Thursday, November 2nd. They set a “neutral” rating and a $256.00 price objective for the company. Zacks Investment Research lowered Humana from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 17th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $257.00 price target on shares of Humana in a report on Friday, October 13th. Thirteen equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $252.81.
Humana (NYSE HUM) traded down $3.07 during trading on Friday, reaching $244.39. The company had a trading volume of 1,265,400 shares, compared to its average volume of 1,376,685. The stock has a market capitalization of $34,913.58, a PE ratio of 20.85, a PEG ratio of 1.68 and a beta of 0.91. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.61 and a current ratio of 1.61. Humana has a 12 month low of $186.25 and a 12 month high of $264.56.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, beating analysts’ consensus estimates of $3.27 by $0.12. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $13.41 billion. Humana had a return on equity of 15.99% and a net margin of 3.49%. Humana’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.18 earnings per share. equities research analysts anticipate that Humana will post 11.64 EPS for the current fiscal year.
In related news, insider Elizabeth D. Bierbower sold 9,786 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $259.00, for a total transaction of $2,534,574.00. Following the completion of the transaction, the insider now directly owns 18,042 shares of the company’s stock, valued at $4,672,878. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider William Kevin Fleming sold 3,071 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total value of $770,759.58. Following the transaction, the insider now directly owns 7,681 shares of the company’s stock, valued at $1,927,777.38. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,660 shares of company stock valued at $5,319,600. 0.80% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in HUM. Vanguard Group Inc. raised its position in Humana by 1.6% during the second quarter. Vanguard Group Inc. now owns 9,892,635 shares of the insurance provider’s stock valued at $2,380,366,000 after purchasing an additional 157,868 shares during the period. FMR LLC raised its position in Humana by 29.3% during the second quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock valued at $1,571,264,000 after purchasing an additional 1,479,210 shares during the period. Capital Research Global Investors raised its position in Humana by 9.7% during the second quarter. Capital Research Global Investors now owns 3,907,333 shares of the insurance provider’s stock valued at $940,182,000 after purchasing an additional 346,069 shares during the period. Renaissance Technologies LLC raised its position in Humana by 1.5% during the second quarter. Renaissance Technologies LLC now owns 2,731,100 shares of the insurance provider’s stock valued at $657,157,000 after purchasing an additional 39,400 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Humana by 2.7% during the second quarter. Bank of New York Mellon Corp now owns 2,016,141 shares of the insurance provider’s stock valued at $485,124,000 after purchasing an additional 53,664 shares during the period. 96.15% of the stock is owned by institutional investors.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.